European Medicines Agency

Doc. Ref. EMEA/351778/2009
P/117/2009

EUROPEAN MEDICINES AGENCY DECISION

of 16 June 2009

on the granting of a product specific waiver for Recombinant human anti-Rhesus D monoclonal antibody (LFB-R593) (EMEA-000512-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 16 June 2009

on the granting of a product specific waiver for Recombinant human anti-Rhesus D monoclonal antibody (LFB-R593) (EMEA-000512-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by LFB Biotechnologies on 30 January 2009 under Article 13 of Regulation (EC) No 1901/2006 as amended,

Having regard to the Opinion of the Paediatric Committee of the European Medicines Agency, issued on 30 April 2009 in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee has an opinion on the granting of a product specific waiver,

(2) It is therefore appropriate to adopt a Decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A waiver for Recombinant human anti-Rhesus D monoclonal antibody (LFB-R593), intravenous use, intramuscular use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to LFB Biotechnologies, 3, avenue des Tropiques, 91942 Les Ulis, France.

Done at London, 16 June 2009

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Doc. Ref. EMEA/PDCO/241218/2009
EMEA-000512-PIP01-08

OPINION OF THE PAEDIATRIC COMMITTEE ON THE GRANTING OF A PRODUCT-SPECIFIC WAIVER

Scope of the application

Active substance(s):
Recombinant human anti-Rhesus D monoclonal antibody (LFB-R593)

Condition(s):
Rh(D) alloimmunisation

Pharmaceutical form(s):
Solution for injection

Route(s) of administration:
Intravenous use
Intramuscular use

Name/corporate name of the waiver applicant:
LFB Biotechnologies

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, LFB Biotechnologies submitted to the EMEA on 30 January 2009 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 5 March 2009.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report, to grant a product-specific waiver for all subsets of the paediatric population and all of the above mentioned condition(s) in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex and appendix.

London, 30 April 2009

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

GROUNDS FOR THE GRANTING OF THE WAIVER

GROUNDS FOR THE GRANTING OF THE WAIVER

The waiver applies to:

- **Condition**

Rh(D) alloimmunisation

Age group: All subsets of the paediatric population from birth to less than 18 years of age, for the solution for injection for intravenous use and intramuscular use,

on the grounds that measures would not be justified by expected therapeutic benefit as needed as efficacy and safety can be extrapolated from adults to children.